|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a case of CD30 (Ki-1)-positive LyP which developed recurrently and was confined to the periorbital areas.
|
19335692 |
2009 |
|
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aggregate results of these studies indicate that the t(2;5) translocation or other somatic mutations resulting in inappropriate expression of ALK are involved rarely if at all in the pathogenesis of Hodgkin's disease, but may be present in about 10% of cases of lymphomatoid papulosis and 20% of cases of CD30+ primary cutaneous large cell lymphoma.
|
9638979 |
1998 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-eight LyP lesions were classified histologically and analysed further with immunostaining for CD3 and CD30.
|
10025972 |
1998 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary cutaneous CD30 (Ki-1)+ large cell lymphoma (KiL) and lymphomatoid papulosis (LyP) type A are collectively termed as primary cutaneous CD30-positive lymphoproliferative disorders.
|
8941669 |
1996 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis and cutaneous CD30+ lymphoma.
|
8806956 |
1996 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The spectrum of cutaneous CD30-positive lymphoproliferative disorders (LPDs) includes lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
|
25349176 |
2014 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Retrospective case series study with immunohistochemical analysis using anti-CD30 and anti-5-hmC antibodies in control (n = 19), lymphomatoid papulosis (LyP) (n = 27) and primary cutaneous anaplastic large cell lymphoma (ALCL) (n = 14) specimens.
|
25353265 |
2014 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This new form of LyP is characterized by oligolesional papules that rapidly ulcerate and evolve into large necrotic eschar-like lesions with a diameter of 1 to 4 cm and an angiocentric and angiodestructive infiltrate of small-sized to medium-sized atypical lymphocytes expressing CD30 and frequently CD8.
|
23026936 |
2013 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purportedly, CD30 is useful in the differential diagnosis between insect bites and lymphomatoid papulosis.
|
12826883 |
2003 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cutaneous CD30+ lymphoproliferative disorders constitute many cutaneous T-cell lymphomas and comprise lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL).Both have an excellent prognosis.
|
31466587 |
2019 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overlapping features of LyP and pcALCL with themselves and with other cutaneous and systemic lymphomas emphasize the importance of careful clinicopathologic correlation and staging in the diagnosis of CD30+ T-LPD.
|
27993440 |
2017 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A skin biopsy revealed a dermal infiltrate of CD4, CD8 and CD30-positive T-cells, consistent with lymphomatoid papulosis.
|
23713913 |
2014 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CD30, which defines anaplastic large cell lymphoma (ALCL) and lymphomatoid papulosis, might also occur in a subset of patients with MF, with or without large-cell transformation.
|
29806104 |
2018 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30+ lymphomas and lymphomatoid papulosis, suggesting that c-kit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors.
|
15105813 |
2004 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Within this nosologic umbrella are nodular and diffuse infiltrates resembling low grade T and B cell lymphoma consistent with lymphocytoma cutis, drug associated reversible T cell dyscrasias which draw a strong morphologic and phenotypic parallel with mycosis fungoides and the various pre-lymphomatous T cell dyscrasias, and angiocentric CD30 positive infiltrates mirroring lymphomatoid papulosis.
|
29361381 |
2018 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This points to a molecular aetiology of primary cutaneous ALC lymphomas and LyP distinct from that of extracutaneous CD30+ lymphoproliferative disease.
|
9415224 |
1997 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In situ hybridization studies showed positivity of the neoplastic cells for EBER in two of 16 cases of CD30+ ALCL and in none of the cases of LyP.
|
17076712 |
2006 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary cutaneous ALCL (C-ALCL) is part of the spectrum of CD30+ lymphoproliferative diseases of the skin including lymphomatoid papulosis.
|
20669794 |
2010 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this article is to review the pathologic and clinical spectrum of ALCL, including the borderline with Hodgkin's disease and lymphomatoid papulosis and to discuss the use of the t(2;5) in better defining a more specific molecular pathologic entity within this group of diseases with CD30 expression.
|
9894470 |
1999 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
T-cell lymphoma represented 78.7% of all cases, the majority being early mycosis fungoides (MF) (64%; median age: 66 years), followed by lymphomatoid papulosis (LyP) (19%; median: age 48 years), and others (median age: 72 years), including eight cases of anaplastic large CD30+ T-cell lymphoma, four CD4+ small-medium pleomorphic T-cell lymphoproliferative disorder, four Sézary syndrome, one subcutaneous panniculitis-like T-cell lymphoma, one extranodal NK/T-cell lymphoma nasal-type, and one angioimmunoblastic T-cell lymphoma.
|
29171395 |
2018 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides).
|
21169992 |
2011 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is a chronic, recurrent lymphoproliferative disorder of the skin that belongs to the group of primary cutaneous CD30-positive T-cell lymphomas.
|
11168749 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies of genetic variants of the CD30 promoter showed distinct microsatellite alleles associated with development of LyP and lymphoma progression.
|
17387297 |
2007 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides.
|
30520526 |
2019 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of t(2;5) in a subset of CD30+ cutaneous lymphoma and LP may indicate a common pathogenesis with a subset of anaplastic nodal lymphoma.
|
8701987 |
1996 |